Neurotechnology pain-relief device company SPR Therapeutics has increased its series A round of investment to $1 million and hopes to push the number up to $2 million, according to a regulatory document. CEO Maria Bennett said earlier this year that Cleveland-area SPR was targeting a $2 million round to beef up its sales and marketing staff. Bennett didn’t return a call yesterday. SPR has received investments from state-backed venture development group JumpStart and NDI Healthcare Fund, a neurotechnology investment fund that was publicly announced earlier this year.